dermatomyositis Archives - Page 23 of 28

Abstract Number: 2287 • 2018 ACR/ARHP Annual Meeting
Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Anthony Fernandez, Dermatology and Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Cutaneous dermatomyositis (DM) is often refractory to multiple medications, suggesting better treatments are needed. Adrenocorticotropic hormone gel is a repository corticotropin injection that is…
Abstract Number: 2291 • 2018 ACR/ARHP Annual Meeting
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
Iago Pinal-Fernandez^1,2, Katherine Pak³, Maria Casal-Dominguez^4,5, Wilson Huang⁴, Jemima Albayda⁶, Eleni Tiniakou⁷, Julie J. Paik¹, Christopher A. Mecoli⁸, Sonye K. Danoff⁹, Lisa Christopher-Stine⁹ and Andrew Mammen^3,10, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵Johns Hopkins Medical School, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Autoantibodies targeting the Mi-2 (Mi-2a and Mi-2b) nuclear antigen in patients with dermatomyositis (DM) were first described in 1985. However, little is known about…
Abstract Number: 373 • 2018 ACR/ARHP Annual Meeting
The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data
Maja Spiritovic^1,2, Sabina Oreska^2,3, Hana Storkanova^2,3, Barbora Hermankova^1,2, Petr Cesak⁴, Adela Rathouska², Katerina Kubinova^2,3, Martin Klein^2,3, Lucia Vernerova^2,3, Olga Ruzickova^2,5, Herman F Mann^2,6, Karel Pavelka^2,3, Ladislav Šenolt^2,3, Jiri Vencovsky^2,7 and Michal Tomcik^2,3, ¹Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Muscle inflammation and weakness, subsequent atrophy and permanent muscle damage in idiopathic inflammatory myopathies (IIM) lead to impaired function, reduced muscle strength, endurance and…
Abstract Number: 2130 • 2017 ACR/ARHP Annual Meeting
Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain
Larissa Valor¹, Diana Hernández-Flórez², Julia Martínez-Barrio³, Beatriz E. Joven⁴, Laura Nuño⁵, Carmen Larena⁶, Irene Llorente⁷, Carmen Barbadillo⁸, Paloma Garcia De La Peña⁹, Lucía Ruíz Gutiérrez¹⁰, Henry Moruno Cruz¹¹, Tatiana Cobo-Ibáñez¹², Raquel Almodóvar González¹³, Leticia Lojo¹⁴, MARIA JESUS GARCIA DE YEBENES Y PROUS¹⁵ and Francisco Javier López Longo¹⁶, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, ³Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Rheumatology, H.U. La Princesa, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁹Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ¹⁰Pediatric Rheumathology Unit, University Children's Hospital Niño Jesús, Madrid, Spain, ¹¹University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹³Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario La Paz, Spain, Spain, ¹⁵Institute for Musculoskeletal Health, Madrid, Spain, ¹⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogeneous group of autoimmune conditions characterized by muscle non-suppurative inflammation, progressive muscle weakness and a variety of extra-muscular…
Abstract Number: 2132 • 2017 ACR/ARHP Annual Meeting
Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis
Ken Yoshida^1,2, Haruyasu Ito¹, Kazuhiro Furuya¹, Taro Ukichi¹, Kentaro Noda¹ and Daitaro Kurosaka¹, ¹Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: We previously showed that fasciitis is a frequent manifestation of the disease in dermatomyositis (DM) but not in polymyositis (PM) and that DM-associated fasciitis…
Abstract Number: 2140 • 2017 ACR/ARHP Annual Meeting
Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry
Lisa G Rider¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Jesse Wilkerson², Abdullah Faiq¹, John McGrath², Hermine I. Brunner³, Bob Goldberg⁴ and Frederick W Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Social and Scientific Systems, Inc., Durham, NC, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴The Myositis Association, Alexandria, VA
Background/Purpose: Myositis is a rare systemic autoimmune disease with suspected environmental and genetic risk factors, but little is known about specific infections and medications that…
Abstract Number: 2141 • 2017 ACR/ARHP Annual Meeting
Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage
Hans Prakash¹, Diego Song¹, Daniel Lichy¹, Pranay Rao², Mina Jain³, Joseph Shrader³, Frederick W Miller⁴, Adam Schiffenbauer⁵, Alexander Gorbach¹ and Lisa G Rider⁵, ¹National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, ²National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, bethesda, MD, ³Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁵Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: To assess microvascular structure and function in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM), we have designed and built a mobile, high-resolution…
Abstract Number: 2147 • 2017 ACR/ARHP Annual Meeting
Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing
Alba Azola¹, Tae Chung², Rachel Mulheren², Genevieve Mckeon², Lisa Christopher-Stine³ and Jeffrey Palmer², ¹Physical Medicine and Rehabilitation, Johns Hopkins University, Lutherville, MD, ²Johns Hopkins University, Baltimore, MD, ³Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The prevalence of dysphagia in patients with inflammatory myopathies has been reported to be as high as 60% (1). Aspiration pneumonia is one of…
Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama^1,2, Ryusuke Yoshimi^1,2, Maasa Tamura^2,3, Naoki Hamada^1,2, Hideto Nagai^1,2, Naomi Tsuchida^1,4, Yosuke Kunishita^1,2, Yutaro Soejima^1,2, Daiga Kishimoto^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^1,5, Yohei Kirino^1,2, Shigeru Ohno^1,6 and Hideaki Nakajima², ¹Y-CURD Study Group, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Y-CURD Study Group, Yokohma, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, ⁶Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
Abstract Number: 2158 • 2017 ACR/ARHP Annual Meeting
HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population
Yukie Yamaguchi¹, Masataka Kuwana², Miwa Kanaoka¹, Tomoya Watanabe¹, Naoko Okiyama³, Takahisa Gono², Masanari Kodera⁴, Takeshi Kambara⁵, Yasuhito Hamaguchi⁶, Mariko Seishima⁷, Kazuhiko Takehara⁶, Manabu Fujimoto³ and Michiko Aihara¹, ¹Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Dermatology, University of Tsukuba, Tsukuba, Japan, ⁴Department of Dermatology, Japan Community Health care Organization Chukyo Hospital, Nagoya, Japan, ⁵Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan, ⁶Department of Dermatology, Kanazawa University, Kanazawa, Japan, ⁷Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan
Background/Purpose: Dermatomyositis (DM) is characterized by inflammation of the skin and skeletal muscle, and is occasionally complicated by interstitial lung disease or concomitant malignancy. It…
Abstract Number: 2159 • 2017 ACR/ARHP Annual Meeting
Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Majid Zeidi^1,2, Peter B Chansky^1,2 and Victoria P Werth^3,4, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, PHILADELPHIA, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose : The use of complementary and alternative medicine (CAM) has gained popularity in the United States over the last few decades. Herbal supplements have…
Abstract Number: 2164 • 2017 ACR/ARHP Annual Meeting
Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies
Masashi Taniguchi¹, Ran Nakashima¹, Nobuo Kuramoto¹, Kosaku Murakami¹, Motomu Hashimoto², Hajime Yoshifuji¹, Masao Tanaka², Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (Abs), which mainly consists of anti-Jo1, PL-7, PL-12, EJ, OJ and KS, are the most common myositis-specific autoantibodies (MSAs). It has…
Abstract Number: 2165 • 2017 ACR/ARHP Annual Meeting
Easily Obtainable Myositis Autoantibody Panel Predictive Factors
Jason Weiner¹, Ryan Jessee², Amanda M. Eudy³, Robert T. Keenan⁴, Michael Datto⁵ and Lisa Criscione-Schreiber⁶, ¹Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Duke University Medical Center, Chapel Hill, NC, ⁴Rheumatology, NYU-HJD, New York, NY, ⁵Department of Pathology, Duke University, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Myositis autoantibodies have diagnostic, therapeutic and prognostic implications, but their utility in clinical practice is unclear. We aimed to describe our institutionÕs ordering practices…
Abstract Number: 2169 • 2017 ACR/ARHP Annual Meeting
A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
Kimberly A. Rehberg¹, Morgan M. Brown², Anna K. Shmagel¹, Elie Gertner³ and Jerry A. Molitor¹, ¹Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²HealthPartners Institute, St. Paul, MN, ³Section of Rheumatology, Regions Hospital, St. Paul, MN
Background/Purpose: Recent studies have suggested the possible benefit of the anti-CD20 agent Rituximab (RTX) in autoimmune myositis (AIM). As AIM is a rare and heterogeneous…
Abstract Number: 2170 • 2017 ACR/ARHP Annual Meeting
Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays
Makoto Miyara¹, Rémi Chieze², Yurdagul Uzunhan³, Jean- Luc Charuel⁴, Pascale Ghillani-Dalbin⁴, Sasi Mudumba⁵, Alice Wu⁵, Hilario Nunes³, Zahir Amoura⁶, Rufus Burlingame⁵ and Lucile Musset¹, ¹Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁴Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁵Genalyte Inc., San Diego, CA, ⁶Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: The presence of anti-MDA5 antibody is associated with amyopathic dermatomyositis and/or rapidly progressive interstitial lung disease that can be fatal.In the latter case, it…

Abstracts tagged "dermatomyositis"

Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers

The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data

Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain

Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis

Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry

Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage

Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing

The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

HLA-DRB104:03/04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population

Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings

Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies

Easily Obtainable Myositis Autoantibody Panel Predictive Factors

A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study

Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays